Table 1.
Demographic and clinical characteristics of the sample.
| Age controls | Age cases | Female (%) | Age of onset | Duration of illness | Total controls | Total cases | MDS-UPDRS | |||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Site | Cohort | Mean (SD) | Mean (SD) | Controls | Cases | Mean (SD) | Mean (SD) | |||
|
| ||||||||||
| Amsterdam | Amsterdam I* | 56.5 (9.6) | 63.3 (10.6) | 37 | 39 | 62.2 (11.2) | 2.1 (2.4) | 43 | 134 | No |
| Amsterdam II | 61.5 (9.5) | 63.4 (7.1) | 40 | 40 | 58.3 (7.9) | 5.3 (3.8) | 25 | 78 | No | |
| Bern | Bern I | 52.7 (9.5) | 63.0 (10.6) | 25 | 54 | 50.0 (10.4) | 12.3 (4.2) | 20 | 50 | Yes |
| Bern II | 67.6 (4.6) | 60.2 (5.6) | 67 | 50 | 47.0 (6.4) | 13.7 (7.9) | 36 | 4 | No | |
| Brisbane | Brisbane I | - | 60.9 (9.5) | - | 24 | NA | 9.7 (6.1) | - | 25 | No |
| Brisbane II | - | 62.3 (9.7) | - | 33 | 54.1 (9.6) | 8.2 (4.2) | - | 58 | No | |
| CapeTown | CapeTown | 68.5 (6.3) | 66.1 (5.6) | 33 | 9 | 60.7 (5.9) | 6.2 (3.8) | 9 | 11 | No |
| Chang Gung | CGU* | 61.0 (7.3) | 59.9 (9.5) | 42 | 43 | 51.8 (10.9) | 8.6 (6.4) | 227 | 322 | No |
| Charlottesville | Charlottesville I | - | 63.7 (9.1) | - | 24 | 54.1 (9.8) | 9.6 (5.1) | - | 92 | Yes |
| Charlottesville II | - | 62.0 (9.0) | - | 13 | 53.4 (9.9) | 8.6 (3.6) | - | 30 | Yes | |
| Charlottesville III | - | 71.3 (6.7) | - | 32 | 63.4 (7.6) | 8.0 (3.2) | - | 22 | Yes | |
| Christchurch | PDNZ | 69.1 (8.2) | 69.3 (7.7) | 35 | 27 | 63.6 (8.6) | 5.6 (5.5) | 52 | 201 | Yes |
| Donders | Donders I** | 62.7 (10.3) | 61.2 (9.9) | 48 | 44 | 58.1 (10.8) | 4.4 (3.9) | 23 | 57 | Yes |
| Donders II* | 59.6 (9.6) | 61.5 (8.9) | 50 | 45 | 58.8 (8.9) | 2.6 (1.5) | 54 | 432 | Yes | |
| Graz | PROMOVE/ASPS I | 63.4 (10.1) | 63.2 (10.4) | 28 | 28 | 58.5 (10.6) | 4.7 (4.6) | 120 | 97 | Yes |
| PROMOVE/ASPS II | - | 64.0 (9.9) | - | 22 | 60.0 (11.1) | 4.0 (3.7) | - | 23 | Yes | |
| Liege | Liege | 64.7 (6.4) | 65.6 (7.3) | 49 | 44 | 58.8 (7.3) | 6.8 (4.6) | 63 | 61 | No |
| Manchester | Manchester | 66.5 (6.9) | 69.0 (7.8) | 54 | 25 | 61.1 (9.6) | 7.6 (4.9) | 35 | 49 | Yes |
| Milan | Milan* | 53.2 (8.3) | 52.5 (6.9) | 71 | 50 | 44.2 (7.8) | 11.3 (6.4) | 21 | 8 | Not available |
| Neurocon | Neurocon | 67.7 (11.5) | 68.7 (10.7) | 86 | 38 | NA | NA | 14 | 26 | Yes |
| ON Japan | Openneuro | 63.3 (5.2) | 66.6 (6.7) | 53 | 54 | NA | NA | 15 | 26 | Not available |
| PPMI | PPMI | 60.3 (10.7) | 61.4 (10.1) | 45 | 40 | 60.8 (10.0) | 0.5 (0.5) | 109 | 228 | Yes |
| Rome SLF | Rome SLF | 37.1 (10.8) | 61.9 (10.5) | 38 | 33 | 57.1 (11.2) | 4.7 (4.4) | 110 | 166 | No |
| Stanford | Stanford I | 62.9 (10.2) | 65.2 (9.7) | 72 | 60 | 60.9 (9.5) | 4.8 (3.3) | 18 | 30 | Yes |
| Stanford II | 70.2 (4.9) | 70.2 (8.0) | 62 | 44 | 65.4 (7.8) | 5.0 (3.5) | 21 | 50 | Yes | |
| Tao Wu | Tao Wu | 63.7 (5.1) | 64.0 (4.0) | 38 | 57 | 59.2 (3.0) | 4.8 (3.9) | 16 | 14 | Not available |
| UCSF | UCSF | 66.0 (6.3) | 63.4 (7.5) | 31 | 38 | NA | NA | 16 | 24 | Yes |
| Udall | Udall | 62.5 (10.0) | 64.9 (9.3) | 61 | 30 | NA | 8.6 (5.0) | 18 | 23 | Not available |
| Campinas | UNICAMP | 60.0 (8.4) | 60.2 (10.2) | 62 | 31 | 52.6 (12.0) | 7.6 (6.6) | 120 | 97 | Yes |
| UPenn | Upenn | 65.2 (6.4) | 70.0 (7.2) | 63 | 33 | 60.3 (8.3) | 9.2 (5.9) | 27 | 49 | Yes |
| Total | 59.9 (11.8) | 63.2 (9.7) | 48 | 38 | 58.0 (10.5) | 5.4 (5.1) | 1212 | 2487 | ||